Liver Metastases From Breast Cancer: What Role for Surgery? Indications and Results
暂无分享,去创建一个
[1] G. Spolverato,et al. Liver Resection for Breast Cancer Liver Metastases: A Cost-utility Analysis , 2017, Annals of surgery.
[2] I. Gibbs,et al. Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] B. Asselain,et al. Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] Bing-he Xu,et al. Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial , 2016, Oncotarget.
[5] C. Hudis,et al. Hepatic Resection or Ablation for Isolated Breast Cancer Liver Metastasis: A Case-control Study With Comparison to Medically Treated Patients , 2016, Annals of surgery.
[6] B. Kang,et al. Extramammary findings on breast MRI: prevalence and imaging characteristics favoring malignancy detection: a retrospective analysis , 2016, World Journal of Surgical Oncology.
[7] Jeffrey E. Lee,et al. Advances in hepatectomy technique: Toward zero transfusions in the modern era of liver surgery. , 2016, Surgery.
[8] J. Samra,et al. Resection of colorectal liver metastases and extra-hepatic disease: a systematic review and proportional meta-analysis of survival outcomes. , 2016, HPB : the official journal of the International Hepato Pancreato Biliary Association.
[9] E. Vibert,et al. Evidence of intermetastatic heterogeneity for pathological response and genetic mutations within colorectal liver metastases following preoperative chemotherapy , 2016, Oncotarget.
[10] H. Miyata,et al. Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21,755 patients from the Japanese breast cancer registry. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] T. Baère,et al. Percutaneous Thermal Ablation of Breast Cancer Metastases in Oligometastatic Patients , 2016, CardioVascular and Interventional Radiology.
[12] D. Pezet,et al. High Resectability Rate of Initially Unresectable Colorectal Liver Metastases After UGT1A1-Adapted High-Dose Irinotecan Combined with LV5FU2 and Cetuximab: A Multicenter Phase II Study (ERBIFORT) , 2016, Annals of Surgical Oncology.
[13] Gary J Whitman,et al. Prognosis for patients with metastatic breast cancer who achieve a no‐evidence‐of‐disease status after systemic or local therapy , 2015, Cancer.
[14] S. Giacchetti,et al. Repeat Hepatectomy for Breast Cancer Liver Metastases , 2015, Annals of Surgical Oncology.
[15] M. Büchler,et al. Is Hepatic Resection for Non-colorectal, Non-neuroendocrine Liver Metastases Justified? , 2015, Annals of Surgical Oncology.
[16] S. Saab,et al. Effects of Yttrium-90 selective internal radiation therapy on non-conventional liver tumors. , 2015, World journal of gastroenterology.
[17] Carsten Denkert,et al. Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial. , 2015, JAMA oncology.
[18] Brice Gayet,et al. Recommendations for laparoscopic liver resection: a report from the second international consensus conference held in Morioka. , 2015, Annals of surgery.
[19] T. Sohda,et al. Why is radiofrequency ablation therapy applied for hepatocellular carcinoma up to 3 nodules and smaller than 3 cm in tumor size? , 2014, Hepato-Gastroenterology.
[20] W. Gradishar,et al. Yttrium-90 radioembolization stops progression of targeted breast cancer liver metastases after failed chemotherapy. , 2014, Journal of vascular and interventional radiology : JVIR.
[21] H. Kuerer,et al. Residual tumor thickness at the tumor-normal tissue interface predicts the recurrence-free survival in patients with liver metastasis of breast cancer. , 2014, Annals of diagnostic pathology.
[22] X. Pivot,et al. A prognostic factor index for overall survival in patients receiving first-line chemotherapy for HER2-negative advanced breast cancer: an analysis of the ATHENA trial. , 2014, Breast.
[23] V. Herlea,et al. Role of surgical treatment in breast cancer liver metastases: a single center experience. , 2014, Anticancer research.
[24] M. Piccart,et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)† , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[25] H. Rugo,et al. Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER , 2014, British Journal of Cancer.
[26] Jinha M. Park,et al. Complete pathologic response of HER2-positive breast cancer liver metastasis with dual Anti-HER2 antagonism , 2014, BMC Cancer.
[27] Seung Ah Lee,et al. Does Liver Resection Provide Long-Term Survival Benefits for Breast Cancer Patients with Liver Metastasis? A Single Hospital Experience , 2014, Yonsei medical journal.
[28] B. Rau,et al. Liver Resections of Isolated Liver Metastasis in Breast Cancer: Results and Possible Prognostic Factors , 2014, HPB surgery : a world journal of hepatic, pancreatic and biliary surgery.
[29] H. Seo,et al. Comparative analysis of radiofrequency ablation and resection for resectable colorectal liver metastases. , 2014, World journal of gastroenterology.
[30] V. Servois,et al. Liver metastases from breast cancer: Surgical resection or not? A case-matched control study in highly selected patients. , 2013, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[31] E. Berber,et al. A comparison of laparoscopic radiofrequency ablation versus systemic therapy alone in the treatment of breast cancer metastasis to the liver. , 2013, HPB : the official journal of the International Hepato Pancreato Biliary Association.
[32] M. Ychou,et al. A Randomized Phase II Trial of Three Intensified Chemotherapy Regimens in First-Line Treatment of Colorectal Cancer Patients with Initially Unresectable or Not Optimally Resectable Liver Metastases. The METHEP Trial , 2013, Annals of Surgical Oncology.
[33] D. Kostov,et al. Prognostic Factors Related to Surgical Outcome of Liver Metastases of Breast Cancer , 2013, Journal of breast cancer.
[34] O. Dirsch,et al. Liver resection in selected patients with metastatic breast cancer: a single-centre analysis and review of literature , 2013, Journal of Cancer Research and Clinical Oncology.
[35] S. Zangos,et al. Thermal ablation therapies in patients with breast cancer liver metastases: A review , 2013, European Radiology.
[36] Ti Zhang,et al. The prognostic analysis of clinical breast cancer subtypes among patients with liver metastases from breast cancer , 2013, International Journal of Clinical Oncology.
[37] E. Van Cutsem,et al. The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. , 2012, The oncologist.
[38] R. van Hillegersberg,et al. Resection of liver metastases in patients with breast cancer: survival and prognostic factors. , 2012, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[39] M. Kanematsu,et al. Diffusion/perfusion MR imaging of the liver: practice, challenges, and future. , 2012, Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine.
[40] P. Bachellier,et al. Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings. , 2012, Annals of surgery.
[41] H. Lee,et al. Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer , 2012, BMC Cancer.
[42] H. Kuerer,et al. Resection of liver metastases from breast cancer: estrogen receptor status and response to chemotherapy before metastasectomy define outcome. , 2012, Surgery.
[43] T. Chua,et al. Hepatic resection for metastatic breast cancer: a systematic review. , 2011, European journal of cancer.
[44] M. Ernst,et al. The role of surgery in metastatic breast cancer. , 2011, European journal of cancer.
[45] B. Skjoldbye,et al. Microwave ablation of liver metastases guided by contrast-enhanced ultrasound: experience with 125 metastases in 39 patients. , 2011, Ultraschall in der Medizin.
[46] E. Winer,et al. International Guidelines for Management of Metastatic Breast Cancer: Can Metastatic Breast Cancer Be Cured? , 2010, Journal of the National Cancer Institute.
[47] J. Ferlay,et al. Estimates of cancer incidence and mortality in Europe in 2008. , 2010, European journal of cancer.
[48] R. J. Haas,et al. Liver resection of colorectal metastases in elderly patients , 2010, The British journal of surgery.
[49] T. Livraghi,et al. Breast cancer liver metastases: US-guided percutaneous radiofrequency ablation--intermediate and long-term survival rates. , 2009, Radiology.
[50] A. Yosepovich,et al. Hormone Receptor Expression Is Associated With a Unique Pattern of Metastatic Spread and Increased Survival Among HER2-Overexpressing Breast Cancer Patients , 2009, American journal of clinical oncology.
[51] R. Adam,et al. R1 Resection by Necessity for Colorectal Liver Metastases: Is It Still a Contraindication to Surgery? , 2008, Annals of surgery.
[52] M. Scotté,et al. Liver resection for breast cancer metastasis: Does it improve survival? , 2008, Surgery Today.
[53] C. Rimkus,et al. [Is liver resection justified for patients with hepatic metastases from breast cancer?]. , 2007, Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen.
[54] Monica Morrow,et al. Local therapy and survival in breast cancer. , 2007, The New England journal of medicine.
[55] E. Winer,et al. Metastatic breast cancer. Recommendations proposal from the European School of Oncology (ESO)-MBC Task Force. , 2007, Breast.
[56] D. Jaeck,et al. Hepatic Resection for Noncolorectal Nonendocrine Liver Metastases: Analysis of 1452 Patients and Development of a Prognostic Model , 2006, Annals of surgery.
[57] A. Giuliano,et al. The utility of estrogen receptor, progesterone receptor, and Her-2/neu status to predict survival in patients undergoing hepatic resection for breast cancer metastases. , 2006, American journal of surgery.
[58] T. Helmberger,et al. Selective internal radiation therapy with SIR-Spheres in patients with nonresectable liver tumors. , 2005, Cancer biotherapy & radiopharmaceuticals.
[59] M. Makuuchi,et al. Hepatic Resection for Metastatic Breast Cancer: Prognostic Analysis of 34 Patients , 2005, World Journal of Surgery.
[60] N. Demartines,et al. Classification of Surgical Complications: A New Proposal With Evaluation in a Cohort of 6336 Patients and Results of a Survey , 2004, Annals of Surgery.
[61] Armando Santoro,et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. , 2004, The New England journal of medicine.
[62] Ping Liang,et al. Prognostic factors for percutaneous microwave coagulation therapy of hepatic metastases. , 2003, AJR. American journal of roentgenology.
[63] G. Hortobagyi,et al. A role for curative surgery in the treatment of selected patients with metastatic breast cancer. , 2003, The oncologist.
[64] M. Druet‐Cabanac,et al. An attempt to clarify indications for hepatectomy for liver metastases from breast cancer. , 2003, American journal of surgery.
[65] G. Gazelle,et al. Percutaneous radio-frequency ablation of liver metastases from breast cancer: initial experience in 24 patients. , 2001, Radiology.
[66] R. Salmon,et al. Résections hépatiques pour métastases de cancer du sein : résultats et facteurs pronostiques (65 cas) , 2001 .
[67] W. Meyers,et al. Liver metastases from breast cancer: long-term survival after curative resection. , 2000, Surgery.
[68] B. Asselain,et al. Hepatic resection in metastatic breast cancer: results and prognostic factors. , 2000, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[69] A. Seidman,et al. Chemotherapy for advanced breast cancer: a current perspective. , 1996, Seminars in oncology.
[70] L. Callans,et al. Recurrent breast cancer: presentation, diagnosis, and treatment. , 1993, Seminars in oncology.
[71] J. Hainsworth,et al. Metastatic breast cancer confined to the skeletal system: An indolent disease☆ , 1986 .
[72] A. Darzi,et al. Recommendations for laparoscopic liver resection : a report from the second international consensus conference held in , 2017 .
[73] C. la Vecchia,et al. Trastuzumab for HER2+ metastatic breast cancer in clinical practice: Cardiotoxicity and overall survival. , 2016, European journal of cancer.
[74] G. Lopes,et al. A cost effectiveness study of eribulin versus standard single-agent cytotoxic chemotherapy for women with previously treated metastatic breast cancer , 2012, Breast Cancer Research and Treatment.
[75] A. Jemal,et al. Global Cancer Statistics , 2011 .
[76] L. Fallowfield,et al. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[77] U. Neumann,et al. Liver resection for metastases from breast cancer , 2008, Journal of surgical oncology.
[78] L. Ellis,et al. Long-term Survival After An Aggressive Surgical Approach in Patients With Breast Cancer Hepatic Metastases , 2004, Annals of Surgical Oncology.
[79] B. Asselain,et al. [Hepatic resection for breast cancer metastases: results and prognosis (65 cases)]. , 2001, Annales de chirurgie.